+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Diseases Therapeutics Market - Global Forecast 2026-2032- Product Image
Liver Diseases Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Liver Diseases Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904957
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Liver Diseases Therapeutics Market is projected to reach USD 21.89 Billion in 2026. It is expected to continue growing at a CAGR of 8.39%, reaching USD 35.63 Billion by 2032.

Liver diseases therapeutics is moving from symptom management toward disease modification, earlier intervention, and precision care across viral hepatitis, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), autoimmune liver disease, cholestatic disorders, cirrhosis, and hepatocellular carcinoma. The opportunity is substantial because liver disease remains a major global health burden: WHO reported 304 million people living with chronic hepatitis B or C in 2022, and viral hepatitis caused about 1.3 million deaths that year.

Demand is also being reshaped by obesity, type 2 diabetes, alcohol-related liver disease, and aging populations. MASLD is estimated to affect roughly one in three adults worldwide, creating a large pool of patients who may require noninvasive diagnostics, cardiometabolic co-management, antifibrotic treatment, and long-term monitoring. For industry leaders, progress will depend on evidence-rich pipelines, payer-ready outcomes data, scalable diagnostics, and integrated care models that connect hepatology, oncology, endocrinology, primary care, and digital health.

Transformative Shifts in the Landscape

The liver diseases therapeutics landscape is undergoing a structural shift as treatment innovation expands beyond antivirals into metabolic, immunologic, fibrotic, and oncology-driven mechanisms. Direct-acting antivirals transformed hepatitis C with cure rates commonly exceeding 95% in appropriate patients, while long-term hepatitis B strategies increasingly focus on functional cure approaches, including immune modulators, RNA-targeted therapies, and combination regimens.

In MASH, the field has entered a new era after the first U.S. FDA approval of a thyroid hormone receptor-beta agonist for adults with noncirrhotic MASH with moderate-to-advanced fibrosis. This milestone is accelerating investment in GLP-1-based metabolic therapies, FGF analogs, pan-PPAR agonists, FXR agonists, antifibrotics, and combination approaches. At the same time, liver cancer therapeutics continue to shift toward immunotherapy combinations, targeted agents, and biomarker-informed sequencing as hepatocellular carcinoma remains one of the leading causes of cancer death globally.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across liver diseases therapeutics by improving risk stratification, clinical trial design, imaging interpretation, and longitudinal disease monitoring. AI-enabled analysis of ultrasound, CT, MRI, elastography, pathology slides, laboratory patterns, and electronic health records can help identify patients with advanced fibrosis, cirrhosis decompensation risk, or hepatocellular carcinoma surveillance gaps earlier than conventional workflows.

For drug developers, AI supports target discovery, patient enrichment, synthetic control modeling, safety signal detection, and adaptive trial operations. In commercial care pathways, predictive analytics can prioritize hepatitis screening, MASLD referral, medication adherence, and transplant evaluation. The highest-value applications will be those validated across diverse populations, integrated into clinician workflows, and governed by transparent model performance, privacy protection, and regulatory-grade evidence.

Key Regional Insights

Asia-Pacific is a pivotal region for liver diseases therapeutics because of its large hepatitis B burden, rising diabetes and obesity rates, and expanding access to advanced diagnostics in China, Japan, South Korea, Australia, India, and ASEAN markets. Growth is increasingly tied to national hepatitis elimination plans, broader liver cancer surveillance, wider availability of noninvasive fibrosis testing, and local clinical trial capacity.

North America remains a leading innovation and reimbursement region, supported by specialty hepatology networks, advanced oncology care, transplant centers, and strong uptake potential for MASH therapies when supported by durable outcomes evidence. Europe benefits from structured health systems, guideline-driven screening, and established health technology assessment processes, although payer scrutiny requires robust cost-effectiveness and real-world evidence. Latin America, led by Brazil and Mexico, shows rising demand for hepatitis treatment, MASLD care, and cirrhosis management, but access variability persists across diagnostics, specialist referral, and reimbursement. The Middle East faces a dual burden of viral hepatitis and metabolic disease, with several health systems investing in prevention, diabetes management, and specialty liver care. Africa has high unmet need in hepatitis B diagnosis, birth-dose vaccination coverage, affordable antiviral access, liver cancer surveillance, and treatment infrastructure, making public health partnerships central to improved outcomes.

Key Group Insights

ASEAN markets are important for scalable hepatitis B management, hepatitis C elimination, and metabolic liver disease screening, especially as urbanization and diabetes prevalence rise across Southeast Asia. The GCC is emerging as a high-priority therapeutic environment because obesity, type 2 diabetes, and MASLD prevalence are elevated, while health systems are investing in specialty care, digital health, preventive screening, and chronic disease management programs.

The European Union is central to evidence-based reimbursement, health technology assessment, and harmonized clinical research, making real-world outcomes essential for access to MASH treatment, hepatitis therapeutics, and hepatocellular carcinoma therapy. BRICS countries combine large patient pools with expanding local manufacturing and clinical trial ecosystems, particularly in China, India, and Brazil, where hepatitis B, MASLD, and liver cancer burdens remain clinically significant. G7 markets continue to lead in specialty drug adoption, oncology innovation, precision diagnostics, and guideline-driven care pathways. NATO membership is not a healthcare market category, but many NATO countries overlap with high-income systems where liver cancer surveillance, MASH treatment, hepatitis elimination, and advanced cirrhosis care are increasingly prioritized.

Key Country Insights

The United States is a leading country for novel MASH therapeutics, hepatocellular carcinoma innovation, transplant hepatology, and high-value specialty care, while Canada emphasizes evidence-based access, public health screening, and integrated hepatitis strategies. Mexico and Brazil face growing MASLD and diabetes-related liver disease burdens, creating demand for affordable diagnostics, antiviral access, hepatology referral networks, and cirrhosis care pathways.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature hepatology infrastructure, strong clinical research participation, and guideline-based management of viral hepatitis, autoimmune liver disease, cholestatic disease, MASH, and liver cancer, while reimbursement decisions increasingly depend on fibrosis improvement, avoidance of decompensation, survival benefit, and quality-of-life evidence. Russia has ongoing demand for viral hepatitis and cirrhosis management, though access dynamics can vary by region and treatment category. China and India represent major clinical need due to hepatitis B, MASLD, diabetes, and liver cancer burdens, alongside expanding domestic research capacity and screening initiatives. Japan, South Korea, and Australia are advanced markets with strong surveillance systems, specialty care, noninvasive diagnostics, and readiness for precision therapeutics across chronic liver disease and hepatocellular carcinoma.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that demonstrate measurable clinical value, including fibrosis regression, reduced progression to cirrhosis, lower decompensation risk, improved survival in liver cancer, and patient-centered quality-of-life outcomes. In MASH, success will depend on pairing pharmacotherapy with noninvasive tests, cardiometabolic management, lifestyle support, and clear treatment algorithms for primary care and hepatology referral.

Organizations should invest in inclusive clinical trials that reflect real-world comorbidities, regional genotype patterns, metabolic risk profiles, alcohol use patterns, and diverse ethnic populations. Market access teams need early health economic models that quantify avoided transplant, hospitalization, cancer, decompensation, and productivity costs. Partnerships with diagnostic developers, AI platforms, payers, public health agencies, providers, and specialty pharmacies can improve screening, adherence, surveillance, and outcomes tracking across the liver disease continuum.

Research Methodology

This executive summary is based on a structured review of publicly available evidence from authoritative sources, including WHO, CDC, EASL, AASLD, IARC, national public health agencies, peer-reviewed hepatology journals, regulatory announcements, clinical guideline updates, and clinical development disclosures. Emphasis was placed on validated epidemiology, approved therapies, late-stage pipeline trends, disease burden indicators, and care delivery patterns.

Insights were synthesized through segmentation by disease area, treatment modality, geography, health system maturity, and access environment. Claims were limited to data-backed observations and widely recognized clinical or regulatory developments, with no reliance on market sizing, market share, or forecasting. The analysis prioritizes relevant themes such as liver diseases therapeutics, MASH treatment, hepatitis B therapeutics, hepatitis C antivirals, liver fibrosis, cirrhosis management, noninvasive liver diagnostics, and hepatocellular carcinoma therapy.

Conclusion

Liver diseases therapeutics is entering a more integrated and innovation-led phase, driven by the convergence of antivirals, metabolic therapies, antifibrotics, immuno-oncology, diagnostics, and artificial intelligence. The largest opportunities will come from earlier identification of at-risk patients, improved treatment persistence, effective surveillance, and therapies that demonstrate durable clinical outcomes rather than biomarker movement alone.

For stakeholders across biopharma, diagnostics, providers, payers, and public health systems, the strategic imperative is clear: build evidence-based, scalable, and equitable liver care models. Organizations that combine strong clinical differentiation with real-world evidence, regional access strategies, and digital-enabled care pathways will be best positioned to lead the next phase of advancement in liver diseases therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Liver Diseases Therapeutics Market, by Disease Type
7.1. Introduction
7.2. Alcoholic Liver Disease
7.3. Hepatitis B
7.4. Hepatitis C
7.5. Liver Cancer
7.5.1. Cholangiocarcinoma
7.5.2. Hepatocellular Carcinoma
7.6. Non Alcoholic Lever Disease
8. Liver Diseases Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. Biologic Immunotherapies
8.3. Cell-Based & Regenerative Therapy
8.4. Gene Therapy
8.5. Microbiome-Modulating Therapies
8.6. Small-Molecule Drugs
9. Liver Diseases Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Liver Diseases Therapeutics Market, by Drug Class
10.1. Introduction
10.2. Antifibrotic
10.2.1. Pirfenidone
10.2.2. Simtuzumab
10.3. Antivirals
10.3.1. Interferons
10.3.2. NS5A Inhibitors
10.3.3. NS5B Polymerase Inhibitors
10.3.4. Nucleotide/Nucleoside Analogues
10.3.5. Protease Inhibitors
10.4. Chemotherapeutic
10.5. Corticosteroids
10.6. Immunosuppressants
10.7. Monoclonal Antibody
11. Liver Diseases Therapeutics Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Home Care Settings
11.4. Hospital
12. Liver Diseases Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Liver Diseases Therapeutics Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Liver Diseases Therapeutics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Liver Diseases Therapeutics Market, by Country
15.1. United States
15.2. Germany
15.3. China
15.4. United Kingdom
15.5. Canada
15.6. India
15.7. Japan
15.8. France
15.9. Italy
15.10. Brazil
15.11. Spain
15.12. Mexico
15.13. Australia
15.14. South Korea
15.15. Russia
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Alnylam Pharmaceuticals, Inc.
17.3. Astellas Pharma Inc.
17.4. AstraZeneca PLC
17.5. Bristol-Myers Squibb Company
17.6. C. H. Boehringer Sohn AG & Co. KG
17.7. Eli Lilly and Company
17.8. F. Hoffmann-La Roche Ltd.
17.9. Genfit S.A.
17.10. Gilead Sciences, Inc.
17.11. GlaxoSmithKline plc
17.12. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
17.13. Johnson & Johnson Services Inc.
17.14. Merck & Co., Inc.
17.15. Moderna, Inc.
17.16. Novartis AG
17.17. Pfizer Inc.
17.18. Sanofi SA
17.19. Takeda Pharmaceutical Company Limited
17.20. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL HEPATITIS C MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL HEPATITIS C MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL HEPATITIS C MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL NON ALCOHOLIC LEVER DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL NON ALCOHOLIC LEVER DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL NON ALCOHOLIC LEVER DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL BIOLOGIC IMMUNOTHERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL BIOLOGIC IMMUNOTHERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL BIOLOGIC IMMUNOTHERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CELL-BASED & REGENERATIVE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CELL-BASED & REGENERATIVE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CELL-BASED & REGENERATIVE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MICROBIOME-MODULATING THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MICROBIOME-MODULATING THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MICROBIOME-MODULATING THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SMALL-MOLECULE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SMALL-MOLECULE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SMALL-MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ANTIFIBROTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIFIBROTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ANTIFIBROTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PIRFENIDONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PIRFENIDONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PIRFENIDONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SIMTUZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SIMTUZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SIMTUZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL INTERFERONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL INTERFERONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL INTERFERONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NS5A INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NS5A INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NS5A INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NUCLEOTIDE/NUCLEOSIDE ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL NUCLEOTIDE/NUCLEOSIDE ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL NUCLEOTIDE/NUCLEOSIDE ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CHEMOTHERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CHEMOTHERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CHEMOTHERAPEUTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL CLINIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 144. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 145. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 146. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 147. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 148. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 149. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 150. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 162. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 164. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 165. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 166. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 167. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 168. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 169. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 170. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 175. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 176. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 177. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 178. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 179. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 180. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 181. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 183. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 184. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 185. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 186. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 187. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 189. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 190. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 191. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 192. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 203. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 205. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 206. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 207. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 208. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 209. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 210. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 211. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 214. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 215. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 216. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 217. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 219. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 220. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 221. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 224. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 225. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 226. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 227. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 229. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 230. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 231. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 245. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 246. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 247. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 248. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 250. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 251. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 252. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 256. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 257. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 258. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 260. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 261. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 262. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 266. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 267. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 268. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 270. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 271. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 272. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 274. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 275. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 276. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 277. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 278. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 280. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 281. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 282. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 284. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 285. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 286. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 287. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 288. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 289. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 290. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 291. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 292. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 294. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 296. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 297. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 298. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 299. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 300. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 301. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 302. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 304. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 306. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 307. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 308. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 309. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 310. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 311. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 312. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 314. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 315. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 316. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 317. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 318. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 319. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 320. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 321. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 322. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 324. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 326. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 327. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 328. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 329. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 330. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 331. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 332. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 336. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2017-2032 (USD MILLION)
TABLE 337. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 338. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 339. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 340. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2017-2032 (USD MILLION)
TABLE 341. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 342. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 343. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHAN

Companies Mentioned

  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genfit S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 21.89 Billion
Forecasted Market Value ( USD ) by 2032 $ 35.63 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Hepatitis Therapeutics Market - Global Forecast 2026-2032 - Product Image

Hepatitis Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Liver Fibrosis Drugs Market - Global Forecast 2026-2032 - Product Image

Liver Fibrosis Drugs Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Liver Diseases Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Liver Diseases Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 125 Pages
  • Global
From
Liver Disease Treatment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Liver Disease Treatment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 350 Pages
  • Global
From
Non-Alcoholic Fatty Liver Disease Therapeutics - Global Strategic Business Report - Product Image

Non-Alcoholic Fatty Liver Disease Therapeutics - Global Strategic Business Report

  • Report
  • 186 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.